A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma

Trial Profile

A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Regorafenib
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms COTEZO; IMblaze370
  • Sponsors Roche
  • Most Recent Events

    • 26 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 May 2017 According to an Exelixis media release, this trial achieved full enrollment in the first quarter of 2017.
    • 03 Apr 2017 Planned End Date changed from 16 Apr 2019 to 7 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top